Celyad is looking for partners for both its cardiology and immuno-oncology programs

Cardiology assets that are available for out-licensing

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Celyad retains Piper Jaffray & Co. to explore strategic alternatives relating to its C-Cure® cardiovascular assets. An exclusive mandate was given to Piper Jaffray, a well reputated international investment bank and asset management firm, to support the company in the partnering and/or the externalization of C-Cure®.  

Immuno-Oncology assets that are available for licensing agreement

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

CAR-T Allogeneic patent: as from November 10th, 2015, our allogeneic T-Cell portfolio includes the US Patent 9,181,527 as well as patent applications relating to allogeneic human primary T-Cells that are engineered to be T-Cell Receptor (TCR)-deficient and express a Chimeric Antigen Receptor (CAR). The granted product claims of the US Patent 9,181,527 are not limited to specific CARs or specific methods of generating allogeneic CAR T-Cells, such as genome editing or genetic engineering. The patented products are applicable for use in treating various human disease conditions such as cancer, chronic infectious diseases, and autoimmunity.

Latest News

Celyad announces new agreements with Celdara Medical and Dartmouth College

Celyad announces new agreements with Celdara Medical and Dartmouth College

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

FDA grants Fast Track designation for Celyad’s ischemic heart failure therapy, C-Cure®

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents

Discover all news

Our partners

Want to see more?

Our partners